ArticleThe Journal of experimental medicine2018
Genome-scale CRISPR-Cas9 screen identifies druggable dependencies in
Open access · bronzeAbstract read
In one paragraph
Article in The Journal of experimental medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
50citing papers in PubMed, 1 pooled it
7.0field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
50 citing papers in PubMed, 1 synthesis or guideline pooled it, 63 citations in OpenAlex.
- The role of PPM1D in cancer and advances in studies of its inhibitors.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2020Pooled it
- Harnessing MDM2-Mediated Targeted Degradation of Transcriptional and Epigenetic Machinery to Disrupt Oncogenic Addictions in Pediatric Sarcoma.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Inhibition of USP7 Destabilizes the Noncanonical PRC1.1 Complex and Induces Neuroblastoma Differentiation.Molecular cancer research : MCR · 2026Article
- UBA1 drives cell cycle to promote malignancy and serves as a therapeutic target in Ewing Sarcoma.BMC cancer · 2026Article
- Seclidemstat (SP-2577) Induces Transcriptomic Reprogramming and Cytotoxicity in Multiple Fusion-Positive Sarcomas.Cancer research communications · 2025Article
- The Role of Deubiquitinating Enzymes in Primary Bone Cancer.Molecular biotechnology · 2025Review
- Identification of small molecule inhibitors of PPM1D using an integrated drug discovery platform.iScience · 2025Article
- Renal ewing sarcoma in a young female: a case report and review of targeted therapy.Frontiers in surgery · 2025Article
- Roles of deubiquitinases in urologic cancers (Review).Oncology letters · 2024Review
- Identification of Small Molecule Inhibitors of PPM1D Using a Novel Drug Discovery Platform.bioRxiv : the preprint server for biology · 2024Article
- Seclidemstat blocks the transcriptional function of multiple FET-fusion oncoproteins.bioRxiv : the preprint server for biology · 2024Article
- Article
- Inhibition of USP7 upregulates USP22 and activates its downstream cancer-related signaling pathways in human cancer cells.Cell communication and signaling : CCS · 2023Article
- Ewing sarcoma treatment: a gene therapy approach.Cancer gene therapy · 2023Review
- Identification of the Stapled α-Helical Peptide ATSP-7041 as a Substrate and Strong Inhibitor of OATP1B1 In Vitro.Biomolecules · 2023Article
- On-Chip Preconcentration Microchip Capillary Electrophoresis Based CE-PRM-LIVE for High-Throughput Selectivity Profiling of Deubiquitinase Inhibitors.Analytical chemistry · 2022Article
- Epigenetic and Transcriptional Signaling in Ewing Sarcoma-Disease Etiology and Therapeutic Opportunities.Biomedicines · 2022Review
- Review
- Novel Targeted Therapeutic Strategies for Ewing Sarcoma.Cancers · 2022Review
- The emerging role of deubiquitylating enzymes as therapeutic targets in cancer metabolism.Cancer cell international · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 4 institutions in 2 countries.
Björn StolteDepartment of Pediatric Oncology, Dana-Farber Cancer Institute and Boston Children's Hospital, Harvard Medical School, Boston, MA.
Amanda Balboni IniguezDepartment of Pediatric Oncology, Dana-Farber Cancer Institute and Boston Children's Hospital, Harvard Medical School, Boston, MA.
Neekesh V DhariaDepartment of Pediatric Oncology, Dana-Farber Cancer Institute and Boston Children's Hospital, Harvard Medical School, Boston, MA.ORCID 0000-0001-5048-067X
Amanda L RobichaudDepartment of Pediatric Oncology, Dana-Farber Cancer Institute and Boston Children's Hospital, Harvard Medical School, Boston, MA.
Amy Saur ConwayDepartment of Pediatric Oncology, Dana-Farber Cancer Institute and Boston Children's Hospital, Harvard Medical School, Boston, MA.ORCID 0000-0003-4583-5127
Ann M MorganDepartment of Pediatric Oncology and the Linde Program in Cancer Chemical Biology, Dana-Farber Cancer Institute, Boston, MA.
Gabriela AlexeDepartment of Pediatric Oncology, Dana-Farber Cancer Institute and Boston Children's Hospital, Harvard Medical School, Boston, MA.ORCID 0000-0002-5668-6297
Nathan J SchauerDepartment of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA.
Xiaoxi LiuDepartment of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA.ORCID 0000-0002-7070-237X
Gregory H BirdDepartment of Pediatric Oncology and the Linde Program in Cancer Chemical Biology, Dana-Farber Cancer Institute, Boston, MA.
Aviad TsherniakThe Broad Institute of MIT and Harvard, Cambridge, MA.ORCID 0000-0002-3797-1877
Francisca VazquezThe Broad Institute of MIT and Harvard, Cambridge, MA.
Sara J BuhrlageDepartment of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA.
Loren D WalenskyDepartment of Pediatric Oncology and the Linde Program in Cancer Chemical Biology, Dana-Farber Cancer Institute, Boston, MA loren_walensky@dfci.harvard.edu.
Kimberly StegmaierDepartment of Pediatric Oncology, Dana-Farber Cancer Institute and Boston Children's Hospital, Harvard Medical School, Boston, MA kimberly_stegmaier@dfci.harvard.edu.ORCID 0000-0003-0218-7895
Broad Institute · USDana-Farber Cancer Institute · USHarvard University · USBoston Children's Hospital · US
Funding
Medical Scientist Training ProgramT32GM007753 · NIGMS · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI WALENSKY, LOREN DAVID · 1985 to 2021
$50.0MMOLECULAR BIOPHYSICS TRAINING GRANTT32GM008313 · NIGMS · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI MURTHY, VENKATESH N · 1989 to 2023
$14.6MDissecting and Targeting Deregulated Mitochondrial Apoptosis in Human CancerR35CA197583 · NCI · DANA-FARBER CANCER INST · PI Loren David Walensky · 2015 to 2026
$12.5MResearch Training in Pediatric OncologyT32CA136432 · NCI · DANA-FARBER CANCER INST · PI SCOTT A ARMSTRONG · 2009 to 2026
$7.9MIntegrating Transforming Approaches to Identify and Target New Vulnerabilities in CancerR35CA210030 · NCI · DANA-FARBER CANCER INST · PI STEGMAIER, KIMBERLY · 2016 to 2022
$7.3MStapled Peptides for Protein Interaction Research and Therapeutic Targeting in Human CancerR50CA211399 · NCI · DANA-FARBER CANCER INST · PI Gregory Howard Bird · 2016 to 2026
$3.2MUSP7 inhibitors for the treatment of multiple myelomaR01CA211681 · NCI · DANA-FARBER CANCER INST · PI BUHRLAGE, SARA J · 2017 to 2019
$1.5MDissecting and targetting HDMX-medicated chemoresistance in human cancerF30CA221087 · NCI · DANA-FARBER CANCER INST · PI CATHCART, ANN MORGAN · 2017 to 2018
$72kNCI NIH HHS F30 CA221087NCI NIH HHS R01 CA211681NCI NIH HHS R35 CA197583NCI NIH HHS R35 CA210030NCI NIH HHS R50 CA211399NCI NIH HHS T32 CA136432NIGMS NIH HHS T32 GM007753NIGMS NIH HHS T32 GM008313
Abstract
Ewing sarcoma is a pediatric cancer driven by EWS-ETS transcription factor fusion oncoproteins in an otherwise stable genomic background. The majority of tumors express wild-type
Indexed as
Genome, HumanAminopyridinesAnimalsCell DeathCell Line, TumorCell ProliferationCell SurvivalCRISPR-Associated Protein 9CRISPR-Cas SystemsDipeptidesDrug SynergismFemaleHumansMice, NudeMutationNeoplasm ProteinsAminopyridinesATSP-7041CRISPR-Associated Protein 9DipeptidesGSK2830371Neoplasm ProteinsP5091Peptides, CyclicThiophenesTP53 protein, humanTumor Suppressor Protein p53
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.